Please ensure Javascript is enabled for purposes of website accessibility

Is VBI Vaccines Stock a Buy?

By Keith Speights – Aug 25, 2020 at 6:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The potential rewards with this biotech stock are high, but so are the risks.

Coming into 2020, you might have expected the only really big story for VBI Vaccines (VBIV -4.94%) would be Sci-B-Vac, its hepatitis B vaccine. While the company has certainly achieved progress in that realm, investors' attention has focused largely on VBI's new vaccine candidate, which targets three types of coronavirus: SARS, MERS, and SARS-CoV-2 (the virus that causes COVID-19).

Both stories have translated into good news for VBI Vaccines this year. The biotech stock is up over 130% year to date in August (down from July, when it skyrocketed by as much as 347% over its January 2020 price). But is VBI Vaccines stock a buy now?

Gloved hands inserting a syringe into a vial.

Image source: Getty Images.


There's no question that the biggest reason to consider buying shares of VBI remains the potential for Sci-B-Vac. The vaccine has already been approved in Israel. VBI announced positive results from a second phase 3 study of Sci-B-Vac in January 2020. Its next step is to secure regulatory approvals in the U.S. and in other key markets, a process that will begin in the fourth quarter of this year.

VBI also has a hepatitis B therapeutic candidate, VBI-2601, that's being evaluated in an ongoing phase 1b/2a clinical study. The biotech expects to report proof-of-concept data from this study within the next few months.

In June, VBI Vaccines presented positive data for experimental glioblastoma cancer vaccine VBI-1901 at the American Association for Cancer Research's annual meeting. The company plans to report data from one arm of an ongoing phase 2a study of the vaccine candidate in the fourth quarter of 2020. It also hopes to initiate a pivotal late-stage study next year.

The program next farthest along in VBI's pipeline is cytomegalovirus (CMV) prophylactic vaccine VBI-1501. While the company received positive feedback from the Food and Drug Administration last year about the design of a phase 2 study for the vaccine candidate, VBI hasn't yet moved forward with the mid-stage clinical trial.

In addition, VBI claims several preclinical programs. The most significant of these is its pan-coronavirus vaccine candidate, VBI-2901. The Canadian government has awarded the company up to 56 million Canadian dollars ($42 million) to fund the development of the experimental vaccine through phase 2 clinical studies.


The biggest knock against VBI Vaccines right now is that it continues to lose a lot of money and isn't anywhere close to achieving profitability. This means that the company will almost certainly have to raise additional cash in the future through stock offerings (which dilute the value of existing shares) or by taking on debt.

There's also a risk that Sci-B-Vac won't become a commercial success. Sales of the vaccine in Israel remain very low and fell year over year in the second quarter of 2020. Although the chances of FDA approval for Sci-B-Vac seem relatively good, it's always possible that the regulatory filing could hit a snag.

Assuming the vaccine does win FDA approval next year, VBI will face stiff competition. GlaxoSmithKline and Merck, two of the biggest drugmakers in the world, market hepatitis B vaccines. Dynavax Technologies is also in the mix with its Heplisav-B vaccine. The total U.S. market for adult hepatitis B vaccines is around $400 million per year. VBI could have a challenge in carving out a significant share of this relatively small market.

After Sci-B-Vac, all of VBI's pipeline candidates have a lot of hurdles to jump before they could potentially win regulatory approval. History shows that the odds are stacked against vaccine candidates in phase 1 and phase 2 testing. 

Is VBI Vaccines stock a buy?

My view is that VBI Vaccines is simply too risky at this point to be a great stock to buy. That's not to say that it can't become a big winner. VBI could move higher after filing for FDA approval of Sci-B-Vac, or after advancing its pan-coronavirus vaccine candidate into clinical testing.

However, the road ahead won't be an easy one for VBI. I think that the stock is one to watch -- but not buy yet. There are other coronavirus stocks that I think offer better risk-reward profiles than VBI right now.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

VBI Vaccines Stock Quote
VBI Vaccines
$0.68 (-4.94%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.